AR and prostate cancer: To evaluate the therapeutic efficacy of the Au‐AR pep‐PROTAC drug in vivo, we established two subcutaneous xenograft mouse models of prostate cancer with C4‐2 cells (5 × 106, AR‐positive) and CWR22rv1 cells (5 × 106, AR&AR‐V7‐positive).